Printer Friendly

American Bio Medica Receives FDA Clearance & is Granted Patent.

KINDERHOOK, N.Y. -- FDA 510(k) Clearance Covers the Rapid TEC(R) Line & Canadian Patent Covers the Rapid Drug Screen(R)

American Bio Medica Corporation (NASDAQ:ABMC) announced today that the US Food and Drug Administration (FDA) has granted the Company 510(k) clearance on its Rapid TEC4 point of collection drug screen. This is the third clearance that the Company has received related to the Rapid TEC product line. The Rapid TEC products contain one individual drug-testing strip that includes the chemistry to detect more than one class of drug. These three clearances allow ABMC to provide its clinical customers with various configurations of 2 to 14 classes of drugs of abuse.

The Company also announced that is has been granted another patent from the Canadian Intellectual Property Office. Patent Number 2,219,529, related to the Company's Rapid Drug Screen product, covers a device for the collection, testing and shipment of body fluid samples. This is the third patent granted this year to ABMC by the Canadian Intellectual Property Office. With this grant, ABMC's intellectual property portfolio for its drug of abuse testing line increases to 8 United States patents and 15 foreign patents, in addition to a number of pending patent applications both within the US and internationally.

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen, Rapid One(R), Rapid TEC and RDS(R) InCup(TM) products test for the presence or absence of drugs of abuse in urine, while OralStat(R) tests for the presence or absence of drugs of abuse in oral fluids. ABMC has been named among the 2002 Deloitte & Touche Technology Fast 500, a listing of the fastest-growing technology companies in North America.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2003, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jan 5, 2005
Words:517
Previous Article:Petrofund Energy Trust Announces Cash Distributions for First Quarter 2005.
Next Article:Fitch Rates Cypress-Fairbanks ISD, Texas $152.4MM School Bonds 'AAA' PSF; Underlying 'AA-'.
Topics:


Related Articles
American Bio Medica Receives FDA Clearance For The 8 Panel Rapid Drug Screen.
American Bio Medica Corp. Third-Quarter Revenue Increases 442 Percent to a New Record.
ABMC Ecstasy Test Receives FDA Clearance; Rapid One Ecstasy Detects Traces of Designer Drug At 1000 ng/mL.
FDA Grants Clearance to ABMC's Rapid One OXY; American Bio Medica Assay the First On-Site Device Cleared for Detecting Misuse of Prescription...
ABMC Granted Product Patent For Nine-panel Drug Test.
FDA Grants Clearance to Startox On-Site Drug Test.
FDA Grants 510-k- Clearance To ABMC's Propoxyphene Test.
ABMC Receives FDA Clearance on Its Rapid Reader; Clearance is the First for an All-Inclusive Drug Screen Interpretation & Data Management System.
American Bio Medica Receives FDA Clearance of Its Rapid TOX(TM).
American Bio Medica Receives FDA Clearance.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters